论文部分内容阅读
目的:观察平消胶囊减轻乳腺癌术后化疗或者术前新辅助患者的不良反应和对免疫功能的影响。方法:选择60例乳腺癌术后患者,分为两组,进行临床疗效观察,治疗组31例,用平消胶囊联合化疗,对照组29例,单用化疗。结果:治疗组显效5例,有效20例,无效6例,有效率为70.96%(25/31);对照组显效1例,有效17例,无效11例,有效率为58.62%(18/28),两组间在化疗临床疗效方面差异有统计学意义(P<0.05)。毒副反应上治疗组WBC下降在化疗后2、3周与对照组比较具有显著性差异(P<0.05),但是化疗后1周与对照组比较无显著差异(P>0.05)。T细胞亚群水平检测示平消胶囊能够提高免疫功能,与治疗前对比有显著性差异(P<0.05)。结论:平消胶囊联合化疗治疗乳腺癌术后患者,疗效显著,毒副作用减少,能增加机体免疫功能及抗癌能力,提高患者的生存率和生存质量。
Objective: To observe the Pingxiao capsule to reduce postoperative chemotherapy of breast cancer or preoperative neoadjuvant patients with adverse reactions and immune function. Methods: Sixty patients with breast cancer were selected and divided into two groups. The clinical effect was observed. The treatment group (31 cases) was treated with Pingxiao capsule combined with chemotherapy and the control group (29 cases) with chemotherapy alone. Results: In the treatment group, 5 cases were markedly effective, 20 cases were effective and 6 cases were ineffective. The effective rate was 70.96% (25/31). In the control group, 1 case was markedly effective, 17 cases effective and 11 cases ineffective. The effective rate was 58.62% (18/28) ), The difference between the two groups in the clinical efficacy of chemotherapy was statistically significant (P <0.05). There was a significant difference (P <0.05) in the decrease of WBC between the two groups after chemotherapy and two weeks after chemotherapy, but there was no significant difference between the two groups (P> 0.05). The level of T cell subpopulation showed that Pingxiao capsule could improve the immune function, which was significantly different from that before treatment (P <0.05). Conclusion: Pingxiao capsule combined with chemotherapy for patients with breast cancer after surgery, significant effect, reduce side effects, can increase immune function and anti-cancer ability and improve patient survival and quality of life.